Generally, tumors harboring KRAS mutations present higher resistance to chemotherapy and EGFR-inhibitors-targeted therapy, including cetuximab and panitumumab, leading to a worse overall survival, especially in CRC [37,48]. The gene discussed is KRAS; the disease is colorectal carcinoma.